[go: up one dir, main page]

WO1998048000A3 - A cell strain with activated anti-cancer cytotoxic activity - Google Patents

A cell strain with activated anti-cancer cytotoxic activity Download PDF

Info

Publication number
WO1998048000A3
WO1998048000A3 PCT/US1998/008240 US9808240W WO9848000A3 WO 1998048000 A3 WO1998048000 A3 WO 1998048000A3 US 9808240 W US9808240 W US 9808240W WO 9848000 A3 WO9848000 A3 WO 9848000A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
patient
obtaining
cytotoxic
cancer cells
Prior art date
Application number
PCT/US1998/008240
Other languages
French (fr)
Other versions
WO1998048000A2 (en
Inventor
John C Hiserodt
Original Assignee
Univ California
John C Hiserodt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, John C Hiserodt filed Critical Univ California
Priority to AU71545/98A priority Critical patent/AU7154598A/en
Publication of WO1998048000A2 publication Critical patent/WO1998048000A2/en
Publication of WO1998048000A3 publication Critical patent/WO1998048000A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The disclosed invention encompasses methods for obtaining compositions comprising cell populations enriched for cancer-specific, cytotoxic T-lymphocytes. The methods comprise the steps of obtaining cancer cells from a patient, obtaining leukocytes from the patient, and co-culturing the cancer cells with the leukocytes to allow outgrowth of a cancer-specific cytotoxic T-lymphocyte (CSCTL) population. In certain embodiments, the method includes the additional step of inducing an anti-cancer immune response in the patient. Substantially pure populations of CSCTLs are provided that are cytotoxic toward autologous cancer cells, and particularly suitable for treating glioblastomas and other solid tumors. This invention further provides methods for treating cancer in a patient using cellular compositions of the invention, and use of cellular compositions for preparing medicaments for cancer treatment.
PCT/US1998/008240 1997-04-23 1998-04-23 A cell strain with activated anti-cancer cytotoxic activity WO1998048000A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU71545/98A AU7154598A (en) 1997-04-23 1998-04-23 A cell strain with activated anti-cancer cytotoxic activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4460197P 1997-04-23 1997-04-23
US60/044,601 1997-04-23

Publications (2)

Publication Number Publication Date
WO1998048000A2 WO1998048000A2 (en) 1998-10-29
WO1998048000A3 true WO1998048000A3 (en) 1999-01-28

Family

ID=21933268

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/008240 WO1998048000A2 (en) 1997-04-23 1998-04-23 A cell strain with activated anti-cancer cytotoxic activity

Country Status (2)

Country Link
AU (1) AU7154598A (en)
WO (1) WO1998048000A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001029191A1 (en) * 1999-10-21 2001-04-26 Keisuke Teshigawara Method of in vitro culture of lymphocytes and gene therapy compositions

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0690125A2 (en) * 1994-06-28 1996-01-03 The Institute Of Physical & Chemical Research Process for induction culture of cytotoxict lymphocytes having killing activity against tumor cells
US5484596A (en) * 1984-01-31 1996-01-16 Akzo N.V. Active specific immunotherapy
WO1996029394A1 (en) * 1995-03-17 1996-09-26 The Regents Of The University Of California Method for treating tumors
WO1998004282A1 (en) * 1996-07-25 1998-02-05 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with allogeneic cytokine-secreting cells
WO1998016238A2 (en) * 1996-10-11 1998-04-23 The Regents Of The University Of California Cancer immunotherapy using tumor cells combined with mixed lymphocytes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484596A (en) * 1984-01-31 1996-01-16 Akzo N.V. Active specific immunotherapy
EP0690125A2 (en) * 1994-06-28 1996-01-03 The Institute Of Physical & Chemical Research Process for induction culture of cytotoxict lymphocytes having killing activity against tumor cells
WO1996029394A1 (en) * 1995-03-17 1996-09-26 The Regents Of The University Of California Method for treating tumors
WO1998004282A1 (en) * 1996-07-25 1998-02-05 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with allogeneic cytokine-secreting cells
WO1998016238A2 (en) * 1996-10-11 1998-04-23 The Regents Of The University Of California Cancer immunotherapy using tumor cells combined with mixed lymphocytes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J.R. SPORN ET AL.,: "Adoptive immunotherapy with peripheral blood lymphocytes cocultured in vitro with autologous tumor cells and interleukine", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, vol. 37, no. 3, 1993, Sttutgart, DE, pages 175 - 180, XP002081415 *
N.J. CROWLEY ET AL.,: "Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas", CANCER RESEARCH, vol. 50, no. 1, 1990, pages 492 - 495, XP002066686 *
R. S. YAMAMOTO ET AL.,: "Generation of stimulated, lymphokine activated T killer (T-LAK) cells from peripheral blood of normal donors and adult patients with recurrent glioblastoma", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 137, 1991, pages 225 - 235, XP002081416 *

Also Published As

Publication number Publication date
WO1998048000A2 (en) 1998-10-29
AU7154598A (en) 1998-11-13

Similar Documents

Publication Publication Date Title
Kang et al. CD11b+ macrophages that infiltrate human epidermis after in vivo ultraviolet exposure potently produce IL-10 and represent the major secretory source of epidermal IL-10 protein.
Niederwieser et al. IFN-mediated induction of MHC antigen expression on human keratinocytes and its influence on in vitro alloimmune responses.
CA2046916A1 (en) Methods and compositions for treatment of cancer using oligonucleotides
Vora et al. Antigen presentation by human dermal microvascular endothelial cells. Immunoregulatory effect of IFN-gamma and IL-10.
Matar et al. Mechanism of antimetastatic immunopotentiation by low-dose cyclophosphamide
Cao et al. Keratinocytes Induce Local Tolerance to Skin Graft by Activating Interleukin-10–Secreting T Cells in the Context of Costimulation Molecule B7-H11
IL123642A (en) Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration
Gallinger et al. Comparison of cellular immunotherapies and anti-CD3 in the treatment of MCA-38-LD experimental hepatic metastases in C57BL/6 mice
Klinkert Rat bone marrow precursors develop into dendritic accessory cells under the influence of a conditioned medium
WO1998048000A3 (en) A cell strain with activated anti-cancer cytotoxic activity
Kuge et al. Interleukin‐12 augments the generation of autologous tumor‐reactive CD8+ cytotoxic T lymphocytes from tumor‐infiltrating lymphocytes
EP0953351A3 (en) Medicaments containing, as the main ingredient, allogenic activated-CD4+ cells and method for producing the same
EP0460065B1 (en) A process for the generation of proliferating cd4 lymphocytes
Varney et al. Expression of interleukin-10 in isolated CD8+ T cells and monocytes from growth factor-mobilized peripheral blood stem cell products: a mechanism of immune dysfunction
Brandau et al. In vitro generation of bacillus Calmette-Guerin-activated killer cells
Belfrage et al. Combined activation of murine lymphocytes with staphylococcal enterotoxin and interleukin-2 results in additive cytotoxic activity
Toledano et al. Interferon-γ (IFN-γ) and interleukin-2 in the generation of lymphokine-activated killer cell cytotoxicity—IFN-γ-induced suppressive activity
US5846928A (en) Method for treating cancer patients
Rogalski et al. Immunomodulators in the treatment of cutaneous lymphoma
Sloan et al. Human autologous dendritic cell-glioma fusions: feasibility and capacity to stimulate T cells with proliferative and cytolytic activity
Tsai et al. Effect of IFN‐γ treatment and in vivo passage of murine tumor cell lines on their sensitivity to lymphokine‐activated killef (LAK) cell lysis in vitro; association with H‐2 expression on the target cells
Schöndorf et al. Immunologic Features of Tumor-Infiltrating Lymphocytes and Peripheral Blood Lymphocytes in Overian Cancer Patients
Parrado et al. Repopulation of circulating T, B and NK lymphocytes following bone marrow and blood stem cell transplantation
Schneekloth et al. Low-Dose lnterleukin-2 in Combination with Interferon-α Effectively Modulates Biological Response in vivo
Huber et al. Pteridines in the assessment of lymphocyte activation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998546352

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA